aica ribonucleotide and Allergic Encephalomyelitis

aica ribonucleotide has been researched along with Allergic Encephalomyelitis in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Choi, S; Samuvel, DJ; Saxena, N; Singh, AK; Singh, I; Won, J1
Giri, S; Nath, N; Prasad, R; Salem, ML; Singh, AK; Singh, I1
Giri, S; Nath, N; Prasad, R; Singh, AK; Singh, I1
Paintlia, AS; Paintlia, MK; Singh, AK; Singh, I1

Other Studies

4 other study(ies) available for aica ribonucleotide and Allergic Encephalomyelitis

ArticleYear
Combination therapy of lovastatin and AMP-activated protein kinase activator improves mitochondrial and peroxisomal functions and clinical disease in experimental autoimmune encephalomyelitis model.
    Immunology, 2018, Volume: 154, Issue:3

    Topics: Adenosine Triphosphate; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Biomarkers; Cell Line; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Gene Expression; Humans; Lovastatin; Mice; Mitochondria; Peroxisomes; rho-Associated Kinases; rhoA GTP-Binding Protein; Ribonucleotides; Spinal Cord

2018
5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis.
    Journal of immunology (Baltimore, Md. : 1950), 2005, Jul-01, Volume: 175, Issue:1

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Antigen Presentation; Cytokines; DNA-Binding Proteins; Encephalomyelitis, Autoimmune, Experimental; Enzyme Activation; Female; GATA3 Transcription Factor; Glycoproteins; Humans; Immunologic Factors; Interleukin-10; Mice; Mice, Inbred C57BL; Multienzyme Complexes; Multiple Sclerosis; Myelin Proteolipid Protein; Myelin-Oligodendrocyte Glycoprotein; Peptide Fragments; Protein Serine-Threonine Kinases; Ribonucleotides; T-Box Domain Proteins; Th1 Cells; Th2 Cells; Trans-Activators; Transcription Factors

2005
5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial-monocyte interaction.
    Journal of neuroscience research, 2006, Aug-15, Volume: 84, Issue:3

    Topics: Aminoimidazole Carboxamide; Animals; Anti-Inflammatory Agents; Blood-Brain Barrier; Cell Adhesion; Cell Adhesion Molecules; Chemotaxis, Leukocyte; Disease Models, Animal; Down-Regulation; Encephalomyelitis, Autoimmune, Experimental; Endothelial Cells; Female; Inflammation Mediators; Mice; Monocytes; NF-kappa B; Rats; Rats, Inbred Lew; Ribonucleotides; Tumor Necrosis Factor-alpha

2006
Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis.
    The American journal of pathology, 2006, Volume: 169, Issue:3

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Enzyme Activation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Immunoglobulin G; Immunologic Factors; Lovastatin; Multienzyme Complexes; Multiple Sclerosis; Myelin Basic Protein; Protein Serine-Threonine Kinases; Rats; Rats, Inbred Lew; Ribonucleotides; Th1 Cells; Th2 Cells

2006